The Australian subsidiary of CSL Behring is set to develop a plasma-derived therapeutic for the treatment of serious complications in Covid-19 patients.

The company intends to focus on patients whose infection is progressing to the requirement for ventilation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Named Covid-19 Immunoglobulin, the therapeutic will be developed by CSL Behring Australia at its manufacturing facility in Broadmeadows, Victoria.

The first part of the development project will involve production and use of a small batch of Covid-19 Immunoglobulin to create tests for detecting the presence of the antibodies against SARS-CoV-2, the novel coronavirus that causes Covid-19.

In the second part, a larger batch of the therapeutic will be used in safety clinical trials at hospitals across Australia.

Covid-19 Immunoglobulin will be developed using donated plasma of those who have recovered from Covid-19 in Australia. The antibodies in donors’ plasma will be pooled, purified and concentrated to generate Covid-Immunoglobulin or hyperimmune globulin.

The Australian Red Cross Lifeblood (Lifeblood) will collect the plasma. According to estimates, up to 800 plasma donations will be needed to generate enough Covid-19 Immunoglobulin for 50-100 seriously ill patients in the clinical trial.

Lifeblood chief executive Shelly Park said: “Developing this new treatment requires plasma donations from people who have fully recovered from Covid-19, and whose plasma contains high levels of antibodies that can fight the SARS-CoV-2 virus that causes Covid-19.”

CSL Behring will collaborate with the National Blood Authority to develop Covid-19 Immunoglobulin for people in Australia.

Commenting on the company’s announcement, Australia Minister for Health Greg Hunt said: “The Australian Government welcomes the announcement by CSL Behring that Australia will be one of the first countries in the world to start production of a potentially lifesaving plasma-derived treatment for people with Covid-19.”